Myeloablative Autologous Gene Therapy
Showing 26 - 50 of >10,000
Severe Combined Immunodeficiency Due to RAG1 Deficiency Trial in Leiden (Gene therapy)
Recruiting
- Severe Combined Immunodeficiency Due to RAG1 Deficiency
- Gene therapy
-
Leiden, NetherlandsLeiden University Medical Center
Dec 3, 2021
Adenosine Deaminase Deficiency, Severe Combined Immunodeficiencies (SCID) Trial in London (genetic, other, drug)
Completed
- Adenosine Deaminase Deficiency
- Severe Combined Immunodeficiencies (SCID)
- Infusion of autologous EFS-ADA LV CD34+ cells
- +3 more
-
London, United KingdomGreat Ormond Street Hospital for Children NHS Foundation Trust
Aug 20, 2021
Leukocyte Adhesion Defect - Type I Trial in Los Angeles, Madrid, London (RP-L201)
Active, not recruiting
- Leukocyte Adhesion Defect - Type I
- RP-L201
-
Los Angeles, California
- +2 more
Nov 19, 2021
Severe Combined Immunodeficiency, X Linked, Gene Therapy Trial in United Kingdom, United States (autologous CD34+ cell
Recruiting
- Severe Combined Immunodeficiency, X Linked
- Gene Therapy
- autologous CD34+ cell transduced with G2SCID vector
-
Los Angeles, California
- +4 more
Jul 19, 2022
Malignant Tumor Trial in Los Angeles (biological, drug, other, radiation, procedure)
Active, not recruiting
- Malignant Neoplasm
- aldesleukin
- +7 more
-
Los Angeles, CaliforniaUniversity of California at Los Angeles (UCLA )
Dec 1, 2022
P47-Phox, Deficiency of Trial in London (Lentiviral vector transduced CD34+ cells)
Not yet recruiting
- P47-Phox, Deficiency of
- Lentiviral vector transduced CD34+ cells
-
London, United KingdomGreat Ormond Street Hospital
Aug 2, 2022
Sickle Cell Disease Trial in Los Angeles (ßAS3-FB vector transduced peripheral blood CD34+ cells)
Recruiting
- Sickle Cell Disease
- βAS3-FB vector transduced peripheral blood CD34+ cells
-
Los Angeles, CaliforniaUniversity of California, Los Angeles (UCLA)
Apr 9, 2022
Neuroblastoma Trial in Houston (SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP, SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2
Active, not recruiting
- Neuroblastoma
- SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP
- SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP
-
Houston, TexasTexas Children's Hospital
Mar 3, 2022
CIBMTR Research Database
Recruiting
- Autologous Stem Cell Transplantation
- +6 more
-
Minneapolis, Minnesota
- +1 more
Jan 20, 2023
HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma Trial in United States (procedure, drug,
Recruiting
- HIV Infection
- +10 more
- Autologous Hematopoietic Stem Cell Transplantation
- +7 more
-
La Jolla, California
- +3 more
Dec 7, 2022
Metastatic Urothelial Carcinoma Trial in Ramat Gan (Tumor Infiltrating Lymphocytes (TIL), Proleukin)
Recruiting
- Metastatic Urothelial Carcinoma
- Tumor Infiltrating Lymphocytes (TIL)
- Proleukin
-
Ramat Gan, IsraelSheba Medical Center
Feb 8, 2021
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Active, not recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +11 more
- Aldesleukin
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jul 13, 2022
Solid Tumor Trial in United States (NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2)
Suspended
- Solid Tumor
- NeoTCR-P1 adoptive cell therapy
- +2 more
-
Duarte, California
- +8 more
Aug 16, 2022
Sickle Cell Disease Treated With Ex Vivo Gene Therapy
Enrolling by invitation
- Sickle Cell Disease
- Safety and efficacy assessments
-
Birmingham, Alabama
- +11 more
Oct 31, 2022
Sickle Cell Disease Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (Non-myeloablative haploidentical
Not yet recruiting
- Sickle Cell Disease
- Non-myeloablative haploidentical peripheral blood stem celltransplantation with briquilimab and abatacept
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Dec 4, 2023
Mucopolysaccharidosis IH Trial in Milano (Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified
Active, not recruiting
- Mucopolysaccharidosis IH
- Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the α-L-iduronidase cDNA, in their final formulation medium.
-
Milano, ItalyOspedale San Raffaele
Aug 6, 2021
B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma Trial in Valhalla (Polatuzumab vedotin)
Recruiting
- B-cell Lymphoma
- +8 more
- Polatuzumab vedotin
-
Valhalla, New YorkNew York Medical Center
Oct 29, 2021
Advanced Solid Tumor Trial in Lianyungang (KT095 CAR-T injection)
Not yet recruiting
- Advanced Solid Tumor
- KT095 CAR-T injection
-
Lianyungang, Jiangsu, ChinaLianyungang First People's Hospital
Aug 23, 2022
Diabetes 2 Type Treatment With ex Vivo Gene Therapy
Active, not recruiting
- Diabete Type 2
- Mesenchymal Stem Cell
- Long term follow up
-
Kharkov, UkraineInstitute of Bio-Stem Cell Rehabilitation
Oct 13, 2021
Multiple Myeloma Trial in United States (procedure, drug, behavioral)
Completed
- Multiple Myeloma
- One Autologous Transplant
- +5 more
-
Birmingham, Alabama
- +35 more
Oct 19, 2021
Mucopolysaccharidosis Type IIIA Trial in Manchester (Autologous CD34+ cells transduced with a lentiviral vector containing the
Active, not recruiting
- Mucopolysaccharidosis Type IIIA
- Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene
-
Manchester, United KingdomManchester University NHS Foundation Trust
Jul 2, 2021
Sickle Cell Disease Trial in Birmingham, Palo Alto, Saint Louis (GPH101 Drug Product)
Active, not recruiting
- Sickle Cell Disease
- GPH101 Drug Product
-
Birmingham, Alabama
- +2 more
Jan 5, 2023
Sickle Cell Disease Trial in United States (bb1111)
Active, not recruiting
- Sickle Cell Disease
- bb1111
-
Birmingham, Alabama
- +10 more
Dec 9, 2021
Pyruvate Kinase Deficiency Trial in Stanford, Madrid (RP-L301)
Recruiting
- Pyruvate Kinase Deficiency
- RP-L301
-
Stanford, California
- +2 more
Sep 22, 2021